2186 studies found for:    EGFR
Show Display Options
Rank Status Study
21 Terminated A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
22 Not yet recruiting Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
Condition: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Intervention: Drug: EGFR-TKI
23 Unknown  Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
Condition: Metastatic Non-Small-Cell Lung Cancer
Intervention:
24 Not yet recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Osimertinib;   Other: Pharmacological Study;   Drug: Sapanisertib
25 Active, not recruiting Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
26 Active, not recruiting Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
Condition: EGFR Inhibitor-associated Rash
Intervention: Drug: Menadione Topical Lotion
27 Not yet recruiting Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Condition: Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Intervention: Drug: Chidamide with EGFR-TKI
28 Not yet recruiting Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Conditions: Lung Neoplasms;   EGFR Gene Mutations
Intervention: Drug: Osimertinib
29 Completed Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention:
30 Recruiting Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Conditions: NSCLC;   EGFR Mutation
Intervention: Drug: Erlotinib
31 Completed Retrospective Study in a NSCLC M+ p
Condition: EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
32 Recruiting Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EGFR-TKIs;   Radiation: thoracic radiotherapy
33 Active, not recruiting Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Ipilimumab;   Drug: Erlotinib;   Drug: Crizotinib;   Drug: Nivolumab
34 Completed A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Condition: Non-Small Cell Lung Cancer
Intervention:
35 Completed A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
Condition: Non Small Cell Lung Cancer
Intervention:
36 Recruiting PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
37 Recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
Intervention:
38 Active, not recruiting
Has Results
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Condition: Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Intervention: Drug: Gefitinib
39 Completed Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
Condition: Advanced Colorectal Cancer
Intervention: Drug: Cetuximab, irinotecan
40 Active, not recruiting Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   EGFR;   HER-2
Intervention: Drug: BIBW 2992

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years